Literature DB >> 6951322

A comparison of the lethal and kinetic effects of doxorubicin and 4'-epi-doxorubicin in vitro.

B T Hill, R D Whelan.   

Abstract

"In vitro" lethal an kinetic effects of 4'-epi-doxorubicin (EPI-DXR) have been established and compared with those of doxorubicin (14-hydroxy-daunorubicin, adriamycin, NSC-123127, DXR). Both drugs show comparable cytotoxicity against a range of murine and human cell lines. Cytotoxicity increases exponentially with drug concentration and with duration of exposure. EPI-DXR like DXR exerts maximal lethal effects during the late S and G2 phases of the cycle in synchronised NIL8 Syrian hamster cells. Flow microfluorimetric data and measurements of mitotic indices provide evidence of population arrest in G2 with both drugs. Responses of various drug-resistant L5178Y cell lines were similar for DXR and EPI-DXR: (i) DXR-resistant cells exhibit complete cross-resistance to EPI-DXR, (ii) vincristine-resistant cells are cross-resistant to DXR and EPI-DXR, and (iii) methotrexate-resistant and 5-fluorouracil-resistant cells show collateral sensitivity to both drugs. These studies emphasise the similarities of DXR and EPI-DXR.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6951322     DOI: 10.1177/030089168206800106

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  10 in total

1.  A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.

Authors:  David A Alagpulinsa; Srinivas Ayyadevara; Shmuel Yaccoby; Robert J Shmookler Reis
Journal:  Mol Cancer Ther       Date:  2015-12-30       Impact factor: 6.261

2.  Combined effects of epirubicin and tamoxifen on the cell-cycle phases in estrogen-receptor-negative Ehrlich ascites tumor cells.

Authors:  A Aydiner; M Ridvanogullari; D Anil; E Topuz; R Nurten; R Disci
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 3.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 4.  Epirubicin. Clinical pharmacology and dose-effect relationship.

Authors:  J Robert
Journal:  Drugs       Date:  1993       Impact factor: 9.546

5.  Comparative metabolism and elimination of adriamycin and 4'-epiadriamycin in the rat.

Authors:  T W Sweatman; M Israel
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients.

Authors:  O Y Hu; S P Chang; J M Jame; K Y Chen
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Effect of pH and moderate hyperthermia on doxorubicin, epirubicin and aclacinomycin A cytotoxicity for Chinese hamster ovary cells.

Authors:  L Kleeberger; E M Röttinger
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Circadian rhythm and seasonal dependence in the toxicological response of mice to epirubicin.

Authors:  M C Mormont; R von Roemeling; R B Sothern; J S Berestka; T R Langevin; M Wick; W J Hrushesky
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

Review 9.  Clinical pharmacokinetics of epirubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

10.  Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers.

Authors:  Yuri Takahashi; Yasuo Miyoshi; Koji Morimoto; Tetsuya Taguchi; Yasuhiro Tamaki; Shinzaburo Noguchi
Journal:  J Cancer Res Clin Oncol       Date:  2007-02-13       Impact factor: 4.322

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.